Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer
{{output}}
Guidelines currently recommend the early use of second-generation androgen receptor signaling inhibitors (ARSIs) in both castrate-resistant and -sensitive metastatic prostate cancer (with or without chemotherapy) and also in biochemical non-metastatic castrate... ...
